

David Moreno-Ajona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2570118/publications.pdf>

Version: 2024-02-01

282
papers

24,886
citations

11235

73
h-index

8878

150
g-index

285
all docs

285
docs citations

285
times ranked

9017
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel maneuver for diagnosis and treatment of torsional-vertical down beating positioning nystagmus: anterior canal and apogeotropic posterior canal BPPV. <i>Brazilian Journal of Otorhinolaryngology</i> , 2022, 88, 708-716.	0.4	5
2	Neuronal nitric oxide synthase regulates regional brain perfusion in healthy humans. <i>Cardiovascular Research</i> , 2022, 118, 1321-1329.	1.8	11
3	Evaluation of treatment response and symptom progression in 400 patients with visual snow syndrome. <i>British Journal of Ophthalmology</i> , 2022, 106, 1318-1324.	2.1	23
4	The selective 5-HT _{1F} receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache. <i>British Journal of Pharmacology</i> , 2022, 179, 358-370.	2.7	17
5	Areas of cerebral blood flow changes on arterial spin labelling with the use of symmetric template during nitroglycerin triggered cluster headache attacks. <i>NeuroImage: Clinical</i> , 2022, 33, 102920.	1.4	1
6	Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms. <i>Journal of Headache and Pain</i> , 2022, 23, 18.	2.5	11
7	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. <i>Lancet Neurology</i> , The, 2022, 21, 284-294.	4.9	59
8	Synchronized refixation saccades in enhanced VVOR test. A new application for PR score. <i>Journal of Vestibular Research: Equilibrium and Orientation</i> , 2022, 32, 443-451.	0.8	1
9	Speech Recognition During Follow-Up of Patients with Ménière's Disease: What Are We Missing?. , 2022, 18, 14-19.		2
10	Devices for Episodic Migraine: Past, Present, and Future. <i>Current Pain and Headache Reports</i> , 2022, 26, 259-265.	1.3	3
11	Low-Dose Intratympanic Gentamicin for Unilateral Ménière's Disease: Accuracy of Early Vestibulo-Ocular Reflex Gain Reduction in Predicting Long-Term Clinical Outcome. <i>Frontiers in Neurology</i> , 2022, 13, 808570.	1.1	0
12	New Generation Gepants: Migraine Acute and Preventive Medications. <i>Journal of Clinical Medicine</i> , 2022, 11, 1656.	1.0	33
13	Menstruation-related hypersomnia. Electroencephalographic and actigraphic correlation in an underrecognized neuropsychiatric disorder. <i>Sleep Medicine</i> , 2022, 91, 93-95.	0.8	1
14	A Prospective Real-World Study Exploring Associations Between Passively Collected Tracker Data and Headache Burden Among Individuals with Tension-Type Headache and Migraine. <i>Pain and Therapy</i> , 2022, 11, 153-170.	1.5	2
15	Skull Vibration-Induced Nystagmus and High Frequency Ocular Vestibular-Evoked Myogenic Potentials in Superior Canal Dehiscence. <i>Audiology Research</i> , 2022, 12, 202-211.	0.8	5
16	Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. <i>European Journal of Neurology</i> , 2022, 29, 2473-2480.	1.7	9
17	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMIS [®] for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	1.8	6
18	Case Report: Transformation of Visual Snow Syndrome From Episodic to Chronic Associated With Acute Cerebellar Infarct. <i>Frontiers in Neurology</i> , 2022, 13, 811490.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Endolymphatic hydrops in the unaffected ear of patients with unilateral Ménière's disease. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 5591-5600.	0.8	5
20	Defective γ -tocopherol may involve tectorial membrane in familial Meniere disease. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	11
21	KCl-induced repetitive cortical spreading depression inhibiting trigeminal neuronal firing is mediated by 5-HT _{1B/1D} and opioid receptors. <i>Cephalalgia</i> , 2022, 42, 1339-1348.	1.8	2
22	VEMPs and Dysautonomia Assessment in Definite Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): a Case Series Study. <i>Cerebellum</i> , 2021, 20, 717-723.	1.4	13
23	In Response to <i>A New and Faster Method to Assess Vestibular Compensation: A Cross-sectional Study</i> . <i>Laryngoscope</i> , 2021, 131, E582.	1.1	2
24	Headache research in 2020: disrupting and improving practice. <i>Lancet Neurology</i> , The, 2021, 20, 7-8.	4.9	3
25	Eptinezumab for the preventive treatment of migraine. <i>Pain Management</i> , 2021, 11, 113-121.	0.7	7
26	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2021, 397, 51-60.	6.3	178
27	Are some patient-perceived migraine triggers simply early manifestations of the attack?. <i>Journal of Neurology</i> , 2021, 268, 1885-1893.	1.8	34
28	Emerging Targets for Migraine Treatment. <i>Neurology India</i> , 2021, 69, 98.	0.2	5
29	Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?. <i>Neurology India</i> , 2021, 69, 59.	0.2	1
30	The migraine postdrome: Spontaneous and triggered phenotypes. <i>Cephalalgia</i> , 2021, 41, 721-730.	1.8	18
31	Disrupted connectivity within visual, attentional and salience networks in the visual snow syndrome. <i>Human Brain Mapping</i> , 2021, 42, 2032-2044.	1.9	31
32	Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks. <i>Cephalalgia</i> , 2021, 41, 913-933.	1.8	15
33	Targets for migraine treatment: beyond calcitonin gene-related peptide. <i>Current Opinion in Neurology</i> , 2021, 34, 363-372.	1.8	11
34	Cluster headache pathophysiology – insights from current and emerging treatments. <i>Nature Reviews Neurology</i> , 2021, 17, 308-324.	4.9	45
35	Exploding head syndrome (a.k.a. episodic cranial sensory shock) responds to single-pulse transcranial magnetic stimulation. <i>European Journal of Neurology</i> , 2021, 28, 1432-1433.	1.7	1
36	Long-term Efficacy and Safety of Erenumab. <i>Neurology</i> , 2021, 96, .	1.5	25

#	ARTICLE	IF	CITATIONS
37	Migraine: disease characterisation, biomarkers, and precision medicine. <i>Lancet, The</i> , 2021, 397, 1496-1504.	6.3	141
38	21st century headache: mapping new territory. <i>Journal of Headache and Pain</i> , 2021, 22, 19.	2.5	19
39	Indomethacinâ€responsive headachesâ€”A narrative review. <i>Headache</i> , 2021, 61, 700-714.	1.8	20
40	Endolymphatic Hydrops in Fluctuating Hearing Loss and Recurrent Vertigo. <i>Frontiers in Surgery</i> , 2021, 8, 673847.	0.6	8
41	Migraine Is More Than Just Headache: Is the Link to Chronic Fatigue and Mood Disorders Simply Due to Shared Biological Systems?. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 646692.	1.0	22
42	Localised increase in regional cerebral perfusion in patients with visual snow syndrome: a pseudo-continuous arterial spin labelling study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 918-926.	0.9	17
43	Atogepant for the Preventive Treatment of Migraine. <i>New England Journal of Medicine</i> , 2021, 385, 695-706.	13.9	126
44	Characterization of opioidergic mechanisms related to the anti-migraine effect of vagus nerve stimulation. <i>Neuropharmacology</i> , 2021, 195, 108375.	2.0	11
45	Multidisciplinary headache clinic-impact of a new model for headache care in Dubai. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106845.	0.6	1
46	Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. <i>Brain Research</i> , 2021, 1770, 147629.	1.1	16
47	Differential actions of indomethacin: clinical relevance in headache. <i>Pain</i> , 2021, 162, 591-599.	2.0	17
48	Therapeutic targeting of nitroglycerin-mediated trigeminovascular neuronal hypersensitivity predicts clinical outcomes of migraine abortives. <i>Pain</i> , 2021, 162, 1567-1577.	2.0	12
49	Integrating headache trigger management strategies into cognitive-behavioral therapy: A randomized controlled trial.. <i>Health Psychology</i> , 2021, 40, 674-685.	1.3	10
50	Dissociated vestibular test results (caloric and vHIT) in patients with Meniereâ€™s disease are not due to velocity storage malfunction. <i>Hearing, Balance and Communication</i> , 2020, 18, 136-142.	0.1	2
51	Bilateral Vestibular Hypofunction in the Time of the Video Head Impulse Test. <i>Audiology and Neuro-Otology</i> , 2020, 25, 72-78.	0.6	4
52	Recent Advances in the Management of Cluster Headache. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	2
53	Primary cough headache treated with non-invasive vagal nerve stimulation. <i>Neurology</i> , 2020, 95, 593-594.	1.5	9
54	Occipital cortex and cerebellum gray matter changes in visual snow syndrome. <i>Neurology</i> , 2020, 95, e1792-e1799.	1.5	35

#	ARTICLE	IF	CITATIONS
55	Differential medication overuse risk of novel anti-migraine therapeutics. <i>Brain</i> , 2020, 143, 2681-2688.	3.7	37
56	Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack. <i>Headache</i> , 2020, 60, 1244-1258.	1.8	20
57	¹⁸ F-FDG-PET Imaging Patterns in Autoimmune Encephalitis: Impact of Image Analysis on the Results. <i>Diagnostics</i> , 2020, 10, 356.	1.3	36
58	Testing rimegepant for migraine—time to revise the trial design? Authors' reply. <i>Lancet</i> , The, 2020, 395, 1901-1902.	6.3	1
59	Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. <i>Medicine in Drug Discovery</i> , 2020, 7, 100053.	2.3	15
60	Perceptions, experiences, and understandings of cluster headache among GPs and neurologists: a qualitative study. <i>British Journal of General Practice</i> , 2020, 70, e514-e522.	0.7	6
61	An Update on Imaging in Idiopathic Intracranial Hypertension. <i>Frontiers in Neurology</i> , 2020, 11, 453.	1.1	9
62	Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 296-306.	1.7	46
63	Structural and functional footprint of visual snow syndrome. <i>Brain</i> , 2020, 143, 1106-1113.	3.7	58
64	Efficacy and safety of eptinezumab in patients with chronic migraine. <i>Neurology</i> , 2020, 94, e1365-e1377.	1.5	236
65	Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study. <i>Cephalgia</i> , 2020, 40, 828-841.	1.8	28
66	One-year sustained efficacy of erenumab in episodic migraine. <i>Neurology</i> , 2020, 95, e469-e479.	1.5	41
67	PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?. <i>Pain</i> , 2020, 161, 1670-1681.	2.0	39
68	A New and Faster Method to Assess Vestibular Compensation: A Cross-Sectional Study. <i>Laryngoscope</i> , 2020, 130, E911-E917.	1.1	13
69	Elevated circulating metalloproteinase 7 predicts recurrent cardiovascular events in patients with carotid stenosis: a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 93.	0.7	5
70	Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain. <i>British Journal of Pharmacology</i> , 2020, 177, 2478-2486.	2.7	25
71	Visual snow syndrome. <i>Neurology</i> , 2020, 94, e564-e574.	1.5	80
72	CGRP pathway monoclonal antibodies for cluster headache. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 947-953.	1.4	13

#	ARTICLE	IF	CITATIONS
73	Co-activation of rhythms during alpha band oscillations as an interictal biomarker of exploding head syndrome. <i>Cephalalgia</i> , 2020, 40, 949-958.	1.8	5
74	Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. <i>Current Opinion in Neurology</i> , 2020, 33, 309-315.	1.8	62
75	Evolving options for the treatment of cluster headache. <i>Current Opinion in Neurology</i> , 2020, 33, 323-328.	1.8	4
76	The Association Between Parental Migraine and Infant Colic: A Cross-sectional, Web-based, U.S. Survey Study. <i>Headache</i> , 2019, 59, 988-1001.	1.8	14
77	Targeting CGRP and 5-HT _{1F} Receptors for the Acute Therapy of Migraine: A Literature Review. <i>Headache</i> , 2019, 59, 3-19.	1.8	32
78	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 737-745.	6.3	236
79	Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. <i>New England Journal of Medicine</i> , 2019, 381, 142-149.	13.9	235
80	Trial of Galcanezumab in Prevention of Episodic Cluster Headache. <i>New England Journal of Medicine</i> , 2019, 381, 132-141.	13.9	178
81	Managing cluster headache. <i>Practical Neurology</i> , 2019, 19, 521-528.	0.5	27
82	Pathophysiology of Migraine. <i>Neurologic Clinics</i> , 2019, 37, 651-671.	0.8	104
83	Aura and Head pain: relationship and gaps in the translational models. <i>Journal of Headache and Pain</i> , 2019, 20, 94.	2.5	38
84	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019, 39, 1475-1487.	1.8	69
85	Recent Advances in Pharmacotherapy for Episodic Migraine. <i>CNS Drugs</i> , 2019, 33, 1053-1071.	2.7	26
86	Divergent influences of the locus coeruleus on migraine pathophysiology. <i>Pain</i> , 2019, 160, 385-394.	2.0	45
87	Classification of vestibular signs and examination techniques: Nystagmus and nystagmus-like movements. <i>Journal of Vestibular Research: Equilibrium and Orientation</i> , 2019, 29, 57-87.	0.8	79
88	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. <i>Cephalalgia</i> , 2019, 39, 1075-1085.	1.8	107
89	James W. Lance MD. <i>Headache</i> , 2019, 59, 825-827.	1.8	3
90	Primary headache disorders. <i>Neurology: Clinical Practice</i> , 2019, 9, 233-240.	0.8	25

#	ARTICLE	IF	CITATIONS
91	Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. <i>Brain</i> , 2019, 142, 1894-1904.	3.7	191
92	Trigeminal autonomic cephalgias presenting in a multidisciplinary tertiary orofacial pain clinic. <i>Journal of Headache and Pain</i> , 2019, 20, 69.	2.5	11
93	<i>N</i> -Methyl-D-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. <i>European Journal of Neuroscience</i> , 2019, 50, 2847-2859.	1.2	15
94	Air and bone stimulation in vestibular evoked myogenic potentials in patients with unilateral Ménière's disease and in controls. <i>Hearing, Balance and Communication</i> , 2019, 17, 170-178.	0.1	3
95	The discovery and development of inhaled therapeutics for migraine. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 591-599.	2.5	4
96	Teaching NeuroImages: Greater occipital nerve injection. <i>Neurology</i> , 2019, 92, e746-e747.	1.5	1
97	Migraine progression in subgroups of migraine based on comorbidities. <i>Neurology</i> , 2019, 93, e2224-e2236.	1.5	60
98	Imaging the Visual Network in the Migraine Spectrum. <i>Frontiers in Neurology</i> , 2019, 10, 1325.	1.1	46
99	Facial solitary morphea profunda presenting with painful trigeminal neuropathy: A case report. <i>Cephalalgia</i> , 2019, 39, 564-568.	1.8	3
100	Endolymphatic hydrops severity in magnetic resonance imaging evidences disparate vestibular test results. <i>Auris Nasus Larynx</i> , 2019, 46, 210-217.	0.5	12
101	Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. <i>Brain</i> , 2019, 142, 103-119.	3.7	62
102	Cortical abnormalities in episodic migraine: A multi-center 3T MRI study. <i>Cephalalgia</i> , 2019, 39, 665-673.	1.8	60
103	CGRP – a target for acute therapy in migraine: Clinical data. <i>Cephalalgia</i> , 2019, 39, 420-427.	1.8	27
104	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	1.8	245
105	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). <i>Cephalalgia</i> , 2018, 38, 1038-1048.	1.8	113
106	Migraine Therapy: Current Approaches and New Horizons. <i>Neurotherapeutics</i> , 2018, 15, 271-273.	2.1	12
107	Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. <i>Drugs</i> , 2018, 78, 411-437.	4.9	54
108	Vestibulo-ocular reflex gain values in the suppression head impulse test of healthy subjects. <i>Laryngoscope</i> , 2018, 128, 2383-2389.	1.1	35

#	ARTICLE	IF	CITATIONS
109	Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse?. <i>Headache</i> , 2018, 58, 295-297.	1.8	5
110	Dissociated responses to caloric and head impulse stimulation in a case of isolated vestibule-lateral semicircular canal dysplasia. <i>Acta Oto-Laryngologica Case Reports</i> , 2018, 3, 5-10.	0.1	3
111	HTLV-1 myelopathy after renal transplant and antiviral prophylaxis: the need for screening. <i>Journal of NeuroVirology</i> , 2018, 24, 523-525.	1.0	21
112	Migraine is common in patients with sarcoidosis. <i>Cephalalgia</i> , 2018, 38, 2079-2082.	1.8	5
113	Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. <i>Neurotherapeutics</i> , 2018, 15, 304-312.	2.1	76
114	Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study. <i>Headache</i> , 2018, 58, 724-731.	1.8	35
115	Cluster headache and the trigeminal-autonomic reflex: Driving or being driven?. <i>Cephalalgia</i> , 2018, 38, 1415-1417.	1.8	16
116	Comparative effects of traditional Chinese and Western migraine medicines in an animal model of nociceptive trigeminovascular activation. <i>Cephalalgia</i> , 2018, 38, 1215-1224.	1.8	19
117	Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. <i>Cephalalgia</i> , 2018, 38, 959-969.	1.8	153
118	Visual snow syndrome: what we know so far. <i>Current Opinion in Neurology</i> , 2018, 31, 52-58.	1.8	63
119	Gentamicin delivery to the inner ear: Does endolymphatic hydrops matter?. <i>PLoS ONE</i> , 2018, 13, e0207467.	1.1	5
120	Biological insights from the premonitory symptoms of migraine. <i>Nature Reviews Neurology</i> , 2018, 14, 699-710.	4.9	115
121	Galcanezumab in chronic migraine. <i>Neurology</i> , 2018, 91, e2211-e2221.	1.5	399
122	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. <i>Lancet</i> , 2018, 392, 2280-2287.	6.3	348
123	Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1999.	3.8	379
124	Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family. <i>International Journal of Endocrinology</i> , 2018, 1-15.	0.6	9
125	Recent advances in headache neuroimaging. <i>Current Opinion in Neurology</i> , 2018, 31, 379-385.	1.8	44
126	Mathematical Methods for Measuring the Visually Enhanced Vestibulo-Ocular Reflex and Preliminary Results from Healthy Subjects and Patient Groups. <i>Frontiers in Neurology</i> , 2018, 9, 69.	1.1	19

#	ARTICLE	IF	CITATIONS
127	The Gain-Time Constant Product Quantifies Total Vestibular Output in Bilateral Vestibular Loss. <i>Frontiers in Neurology</i> , 2018, 9, 396.	1.1	6
128	Cluster Headache and Calcitonin Gene-Related Peptide—More on Quantum Therapeutics in Headache Medicine. <i>JAMA Neurology</i> , 2018, 75, 1179.	4.5	6
129	Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. <i>Journal of Headache and Pain</i> , 2018, 19, 5.	2.5	35
130	Instrumental head impulse test changes after intratympanic gentamicin for unilateral definite Ménière's disease: A systematic review and meta-analysis. <i>Auris Nasus Larynx</i> , 2018, 45, 943-951.	0.5	9
131	Headache and Ophthalmoparesis: Case Report of an Atypical Incomplete Miller-Fisher Syndrome. <i>Headache</i> , 2018, 58, 746-749.	1.8	4
132	Gray matter volume modifications in migraine. <i>Neurology</i> , 2018, 91, e280-e292.	1.5	49
133	Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium. <i>Neurology</i> , 2018, 91, 167-167.	1.5	1
134	Neuroendocrine signaling modulates specific neural networks relevant to migraine. <i>Neurobiology of Disease</i> , 2017, 101, 16-26.	2.1	40
135	Pathophysiology of Migraine: A Disorder of Sensory Processing. <i>Physiological Reviews</i> , 2017, 97, 553-622.	13.1	1,168
136	Home-Based Trials in Adolescent Migraine. <i>JAMA Neurology</i> , 2017, 74, 744.	4.5	25
137	Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. <i>Neurology</i> , 2017, 89, 279-283.	1.5	12
138	An update on migraine: current understanding and future directions. <i>Journal of Neurology</i> , 2017, 264, 2031-2039.	1.8	106
139	An Update on Non-Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine. <i>Headache</i> , 2017, 57, 685-691.	1.8	48
140	Calcitonin gene-related peptide and pain: a systematic review. <i>Journal of Headache and Pain</i> , 2017, 18, 34.	2.5	161
141	Erenumab (AMG 334) in episodic migraine. <i>Neurology</i> , 2017, 89, 1237-1243.	1.5	120
142	Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. <i>JAMA Neurology</i> , 2017, 74, 1266.	4.5	33
143	Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>New England Journal of Medicine</i> , 2017, 377, 2113-2122.	13.9	573
144	A Controlled Trial of Erenumab for Episodic Migraine. <i>New England Journal of Medicine</i> , 2017, 377, 2123-2132.	13.9	661

#	ARTICLE	IF	CITATIONS
145	The limits of stability in patients with unilateral vestibulopathy. <i>Acta Oto-Laryngologica</i> , 2017, 137, 1051-1056.	0.3	7
146	Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?. <i>Current Treatment Options in Neurology</i> , 2017, 19, 27.	0.7	119
147	Occipital headaches and neuroimaging in children. <i>Neurology</i> , 2017, 89, 469-474.	1.5	25
148	Acute vestibular syndrome with down-beat nystagmus as a sole clinical presentation in AICA transient ischemic attack with an uncommon clinical course. <i>Acta Oto-Laryngologica Case Reports</i> , 2017, 2, 131-136.	0.1	1
149	Vestibulo-Ocular Reflex Stabilization after Vestibular Schwannoma Surgery: A Story Told by Saccades. <i>Frontiers in Neurology</i> , 2017, 8, 15.	1.1	26
150	Diagnostic Bedside Vestibuloocular Reflex Evaluation in the Setting of a False Negative Fistula Test in Cholesteatoma of the Middle Ear. <i>Case Reports in Otolaryngology</i> , 2017, 2017, 1-5.	0.1	7
151	The Role of Melatonin in the Treatment of Primary Headache Disorders. <i>Headache</i> , 2016, 56, 1257-1266.	1.8	74
152	The migraine postdrome. <i>Neurology</i> , 2016, 87, 309-313.	1.5	134
153	The utility of radioisotope cisternography in low CSF/volume syndromes compared to myelography. <i>Cephalalgia</i> , 2016, 36, 1291-1295.	1.8	13
154	Headache. <i>Seminars in Neurology</i> , 2016, 36, 442-448.	0.5	1
155	Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. <i>Neurology</i> , 2016, 87, 2522-2526.	1.5	10
156	Aprepitant for the management of nausea with inpatient IV dihydroergotamine. <i>Neurology</i> , 2016, 87, 1613-1616.	1.5	11
157	Chronic migraine headache prevention with noninvasive vagus nerve stimulation. <i>Neurology</i> , 2016, 87, 529-538.	1.5	191
158	TEV-48125 for the preventive treatment of chronic migraine. <i>Neurology</i> , 2016, 87, 41-48.	1.5	84
159	Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. <i>Pain</i> , 2016, 157, 1666-1673.	2.0	37
160	Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for [¹¹ C]-dihydroergotamine during glyceryl trinitrate-induced migraine. <i>Brain</i> , 2016, 139, 1994-2001.	3.7	66
161	Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. <i>Brain</i> , 2016, 139, 2002-2014.	3.7	105
162	Predictors of Triptan Response in Pediatric Migraine. <i>Pediatric Neurology</i> , 2016, 58, 37-40.	1.0	14

#	ARTICLE	IF	CITATIONS
163	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 382-390.	4.9	312
164	Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. <i>Neurology</i> , 2016, 86, 856-859.	1.5	17
165	Therapeutic illusion: another frontier in Ménière's disease. <i>Annals of Translational Medicine</i> , 2016, 4, S63-S63.	0.7	0
166	A Puzzle of Vestibular Physiology in a Meniere's Disease Acute Attack. <i>Case Reports in Otolaryngology</i> , 2015, 2015, 1-5.	0.1	13
167	Putting migraine to sleep: Rexants as a preventive strategy. <i>Cephalalgia</i> , 2015, 35, 377-378.	1.8	6
168	Reduced efficacy of sumatriptan in migraine with aura vs without aura. <i>Neurology</i> , 2015, 84, 1880-1885.	1.5	28
169	Is migraine a risk factor for pediatric stroke?. <i>Cephalalgia</i> , 2015, 35, 1252-1260.	1.8	41
170	Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. <i>Neurology</i> , 2015, 84, 1249-1253.	1.5	120
171	The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. <i>Neurology</i> , 2015, 84, 1043-1050.	1.5	63
172	Single intratympanic gentamicin injection in Ménière's disease: VOR change and prognostic usefulness. <i>Laryngoscope</i> , 2015, 125, 1915-1920.	1.1	27
173	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. <i>Journal of Neuroscience</i> , 2015, 35, 13800-13806.	1.7	62
174	Incredible progress for an era of better migraine care. <i>Nature Reviews Neurology</i> , 2015, 11, 621-622.	4.9	17
175	The Premonitory Phase of Migraine – What Can We Learn From It?. <i>Headache</i> , 2015, 55, 609-620.	1.8	61
176	Neuronal PAC 1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. <i>Science Translational Medicine</i> , 2015, 7, 308ra157.	5.8	109
177	The effect of intra-tympanic dexamethasone on the vestibular function in patients with recurrent vertigo. <i>Acta Oto-Laryngologica</i> , 2015, 135, 1253-1258.	0.3	1
178	Long-term follow-up of late onset vestibular complaints in patients with cochlear implant. <i>Acta Oto-Laryngologica</i> , 2015, 135, 1245-1252.	0.3	9
179	The relationship between migraine and infant colic: A systematic review and meta-analysis. <i>Cephalalgia</i> , 2015, 35, 63-72.	1.8	40
180	Evidence for orexinergic mechanisms in migraine. <i>Neurobiology of Disease</i> , 2015, 74, 137-143.	2.1	71

#	ARTICLE	IF	CITATIONS
181	BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. <i>Cephalalgia</i> , 2014, 34, 114-125.	1.8	241
182	Stress and migraine: Something expected, something unexpected. <i>Neurology</i> , 2014, 82, 1388-1389.	1.5	10
183	Migraine-like Features in Cluster Headache. <i>Headache</i> , 2014, 54, 555-555.	1.8	1
184	Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: A Fos protein study. <i>Neurobiology of Disease</i> , 2014, 64, 1-7.	2.1	21
185	Recent onset disequilibrium mimicking acute vestibulopathy in early multiple sclerosis. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014, 35, 529-534.	0.6	7
186	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology</i> , The, 2014, 13, 1100-1107.	4.9	333
187	Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Neurology</i> , The, 2014, 13, 885-892.	4.9	332
188	Vestibulo-ocular reflex in patients with superior semicircular canal benign paroxysmal positional vertigo (BPPV). <i>Acta Oto-Laryngologica</i> , 2014, 134, 485-490.	0.3	11
189	Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. <i>Neurology</i> , 2014, 83, 958-966.	1.5	235
190	Hemicrania continua- building on experience and clinical science. <i>Journal of Headache and Pain</i> , 2014, 15, 9.	2.5	5
191	A multicenter observational study on the role of comorbidities in the recurrent episodes of benign paroxysmal positional vertigo. <i>Auris Nasus Larynx</i> , 2014, 41, 31-36.	0.5	101
192	Therapeutic prospects for migraine: Can paradise be regained?. <i>Annals of Neurology</i> , 2013, 74, 423-434.	2.8	22
193	Autonomic nervous system control of the cerebral circulation. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 193-201.	1.0	67
194	Migraine and multiple sclerosis: Epidemiology and approach to treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 73-79.	0.9	22
195	All that is obvious is not clear: What is the origin of throbbing pain in migraine?. <i>Pain</i> , 2013, 154, 970-971.	2.0	3
196	Analysis of occipital nerve stimulation in studies of chronic migraine and broader implications of social media in clinical trials. <i>Cephalalgia</i> , 2013, 33, 214-215.	1.8	17
197	Author's reply on Pathophysiology of migraine. <i>Annals of Indian Academy of Neurology</i> , 2013, 16, 456-7.	0.2	1
198	Pathophysiology of migraine. <i>Annals of Indian Academy of Neurology</i> , 2012, 15, 15.	0.2	112

#	ARTICLE	IF	CITATIONS
199	Trigeminal Autonomic Cephalgias. CONTINUUM Lifelong Learning in Neurology, 2012, 18, 883-895.	0.4	22
200	Before the headache. Neurology, 2012, 79, 1392-1396.	1.5	62
201	A translational in vivo model of trigeminal autonomic cephalgias: therapeutic characterization. Brain, 2012, 135, 3664-3675.	3.7	82
202	Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia, 2011, 31, 712-722.	1.8	251
203	New Daily Persistent Headache: A Syndrome Not a Discrete Disorder. Headache, 2011, 51, 650-653.	1.8	36
204	Trigeminal Neuropathic Pain in a Patient With Progressive Facial Hemiatrophy (Parry-Romberg) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 542	4.9	21
205	A potential nitregeric mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. Journal of Headache and Pain, 2010, 11, 477-483.	2.5	66
206	Current practice and future directions in the prevention and acute management of migraine. Lancet Neurology, The, 2010, 9, 285-298.	4.9	203
207	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology, The, 2010, 9, 373-380.	4.9	413
208	Auditory and Vestibular Assessment of Patients with MÃ©niÃ©reâ€™s Disease Who Suffer Tumarkin Attacks. Audiology and Neuro-Otology, 2010, 15, 399-406.	0.6	24
209	Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain, 2010, 133, 1973-1986.	3.7	148
210	Modulation of nociceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain, 2010, 133, 2540-2548.	3.7	99
211	Trigeminal Autonomic Cephalgias: Paroxysmal Hemicrania, SUNCT/SUNA, and Hemicrania Continua. Seminars in Neurology, 2010, 30, 186-191.	0.5	85
212	CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology, 2010, 6, 573-582.	4.9	418
213	The vascular theory of migraineâ€™ a great story wrecked by the facts. Brain, 2009, 132, 6-7.	3.7	151
214	Neurons of the Dopaminergic/Calcitonin Gene-Related Peptide A11 Cell Group Modulate Neuronal Firing in the Trigemino-cervical Complex: An Electrophysiological and Immunohistochemical Study. Journal of Neuroscience, 2009, 29, 12532-12541.	1.7	105
215	Foreword. Cephalalgia, 2009, 29, v-vi.	1.8	0
216	Pathophysiology of Migraine. Neurologic Clinics, 2009, 27, 335-360.	0.8	123

#	ARTICLE	IF	CITATIONS
217	Occipital Nerve Stimulation for Headache: Mechanisms and Efficacy. <i>Headache</i> , 2008, 48, 313-318.	1.8	68
218	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. <i>Headache</i> , 2008, 48, 799-804.	1.8	17
219	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. <i>Headache</i> , 2008, 48, 1399-1405.	1.8	19
220	Paroxysmal hemicrania: a prospective clinical study of 31 cases. <i>Brain</i> , 2008, 131, 1142-1155.	3.7	160
221	Migraine in pregnancy. <i>BMJ: British Medical Journal</i> , 2008, 336, 1502-1504.	2.4	237
222	Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. <i>Current Opinion in Neurology</i> , 2008, 21, 323-330.	1.8	70
223	Recent advances in understanding migraine mechanisms, molecules and therapeutics. <i>Trends in Molecular Medicine</i> , 2007, 13, 39-44.	3.5	250
224	Neurostimulation in primary headache syndromes. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1785-1789.	1.4	41
225	Emerging therapies for migraine. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 610-619.	2.7	50
226	Trigeminal autonomic cephalalgias: Diagnosis and treatment. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 117-125.	2.0	42
227	Squeezing life into botulinum toxin A in migraine: Imploding versus Exploding Pain. <i>Pain</i> , 2006, 125, 206-207.	2.0	6
228	Zolmitriptan Intranasal: A Review of the Pharmacokinetics and Clinical Efficacy. <i>Headache</i> , 2006, 46, 138-149.	1.8	48
229	Headache: a good year for research. <i>Lancet Neurology</i> , The, 2006, 5, 5-6.	4.9	1
230	Posterior hypothalamic activation in paroxysmal hemicrania. <i>Annals of Neurology</i> , 2006, 59, 535-545.	2.8	190
231	Migraine: emerging treatment options for preventive and acute attack therapy. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 419-427.	1.0	22
232	Analysis of the vestibulo-ocular reflex time constant in patients with benign recurrent vertigo associated with head-shaking nystagmus. <i>Acta Oto-Laryngologica</i> , 2006, 126, 358-363.	0.3	1
233	The Migrainous Brain: What You See Is Not All You Get?. <i>PLoS Medicine</i> , 2006, 3, e404.	3.9	11
234	Recent advances in the diagnosis and management of migraine. <i>BMJ: British Medical Journal</i> , 2006, 332, 25-29.	2.4	55

#	ARTICLE	IF	CITATIONS
235	Migraine Pathophysiology. <i>Headache</i> , 2005, 45, S14-S24.	1.8	139
236	Can we Develop Neurally Acting Drugs for the Treatment of Migraine?. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 741-750.	21.5	64
237	Advances in the understanding of headache. <i>British Medical Bulletin</i> , 2005, 73-74, 83-92.	2.7	20
238	Another migraine gene. <i>Lancet, The</i> , 2005, 366, 345-346.	6.3	15
239	Posterior Hypothalamic and Brainstem Activation in Hemicrania Continua. <i>Headache</i> , 2004, 44, 747-761.	1.8	244
240	Basic Science: Prejunctional and Presynaptic Trigeminovascular Targets: What Preclinical Evidence Is There?. <i>Headache Currents: A Journal for Recent Advances in Headache and Facial Pain</i> , 2004, 1, 1-6.	0.7	4
241	Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. <i>British Journal of Pharmacology</i> , 2004, 142, 1171-1181.	2.7	274
242	The future of headache. <i>Journal of Neurology</i> , 2004, 251, 630-636.	1.8	1
243	Post-triptan era for the treatment of acute migraine. <i>Current Pain and Headache Reports</i> , 2004, 8, 393-398.	1.3	21
244	Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. <i>New England Journal of Medicine</i> , 2004, 350, 1104-1110.	13.9	1,118
245	The trigeminocervical complex and migraine: Current concepts and synthesis. <i>Current Pain and Headache Reports</i> , 2003, 7, 371-376.	1.3	244
246	Hypnic headache. <i>Neurology</i> , 2003, 60, 905-909.	1.5	207
247	Headache (chronic tension type). <i>Clinical Evidence</i> , 2003, , 1432-40.	0.2	0
248	Headache (chronic tension-type). <i>Clinical Evidence</i> , 2003, , 1538-46.	0.2	0
249	Low CSF Volume (Pressure) Headache. <i>Practical Neurology</i> , 2002, 2, 192-197.	0.5	5
250	Migraine - Current Understanding and Treatment. <i>New England Journal of Medicine</i> , 2002, 346, 257-270.	13.9	1,692
251	New directions in migraine research. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 368-373.	0.8	13
252	The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. <i>European Journal of Pharmacology</i> , 2002, 452, 223-228.	1.7	61

#	ARTICLE	IF	CITATIONS
253	Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. <i>Lancet Neurology</i> , The, 2002, 1, 251-257.	4.9	416
254	Migraine Management: Contrasting Patient Preferences With Current Clinical End Points: Introduction. <i>Headache</i> , 2002, 42, 1-2.	1.8	3
255	New daily persistent headache. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72 Suppl 2, ii6-ii9.	0.9	30
256	Chronic daily headache. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72 Suppl 2, ii2-ii5.	0.9	7
257	Hypothalamic involvement and activation in cluster headache. <i>Current Pain and Headache Reports</i> , 2001, 5, 60-66.	1.3	51
258	Effect of Rizatriptan and Other Triptans on the Nausea Symptom of Migraine: A Post Hoc Analysis. <i>Headache</i> , 2001, 41, 754-763.	1.8	38
259	Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. <i>Journal of Anatomy</i> , 2001, 198, 29-35.	0.9	88
260	Neuroimaging in headache. <i>Microscopy Research and Technique</i> , 2001, 53, 179-187.	1.2	29
261	GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. <i>British Journal of Pharmacology</i> , 2001, 134, 896-904.	2.7	36
262	Migraine: Selecting Treatments now and Making Requests for the Future?. <i>Current Medical Research and Opinion</i> , 2001, 17, s98-99.	0.9	2
263	The pharmacology of headache. <i>Progress in Neurobiology</i> , 2000, 62, 509-525.	2.8	228
264	Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. <i>Journal of Anatomy</i> , 1999, 194, 579-588.	0.9	122
265	Helospectin-Like Peptides: Immunochemical Localization and Effects on Isolated Cerebral Arteries and on Local Cerebral Blood Flow in the Cat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 61-67.	2.4	12
266	The Trigeminovascular System in Humans: Pathophysiologic Implications for Primary Headache Syndromes of the Neural Influences on the Cerebral Circulation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 115-127.	2.4	521
267	Advances in the Pharmacotherapy of Migraine. <i>Drugs in R and D</i> , 1999, 2, 361-374.	1.1	20
268	Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat. <i>Pain</i> , 1999, 82, 15-22.	2.0	57
269	The Scientific Basis of Medication Choice in Symptomatic Migraine Treatment. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 20-26.	0.3	36
270	Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. <i>American Journal of Anatomy</i> , 1999, 194, 579-588.	0.9	2

#	ARTICLE	IF	CITATIONS
271	Neuropeptides in headache. <i>European Journal of Neurology</i> , 1998, 5, 329-341.	1.7	84
272	Zolmitriptan, a 5-HT _{1B/1D} receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. <i>European Journal of Neurology</i> , 1998, 5, 535-543.	1.7	52
273	Hypothalamic activation in cluster headache attacks. <i>Lancet, The</i> , 1998, 352, 275-278.	6.3	1,092
274	Serotonin 5-HT _{1B/1D} Receptor Agonists in Migraine. <i>CNS Drugs</i> , 1998, 10, 271-286.	2.7	78
275	Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT _{1B/1D}) receptors. <i>British Journal of Pharmacology</i> , 1997, 122, 918-922.	2.7	106
276	The distribution of trigeminovascular afferents in the nonhuman primate brain <i>Macaca nemestrina</i> : a c-fos immunocytochemical study. <i>Journal of Anatomy</i> , 1997, 190, 367-375.	0.9	214
277	Fortnightly Review: Diagnosis and management of migraine. <i>BMJ: British Medical Journal</i> , 1996, 312, 1279-1283.	2.4	66
278	Peripheral and Central Trigemino-vascular Activation in Cat is Blocked by the Serotonin (5HT)-1 D Receptor Agonist 311C90. <i>Headache</i> , 1994, 34, 394-399.	1.8	170
279	The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. <i>Annals of Neurology</i> , 1993, 33, 48-56.	2.8	1,021
280	Intravenous Acetylsalicylic Acid Inhibits Central Trigeminal Neurons in the Dorsal Horn of the Upper Cervical Spinal Cord in the Cat. <i>Headache</i> , 1993, 33, 541-544.	1.8	81
281	Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. <i>Brain Research</i> , 1993, 629, 95-102.	1.1	239
282	The distribution of trigeminovascular afferents in the nonhuman primate brain <i>Macaca nemestrina</i> : a c-fos immunocytochemical study. , 0, .		3